Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30057869 | 1.00 | ACHE (0.40) | ACHECYP3A4IDO1TDO2CES2 | |
| SCHEMBL213484 | 1.00 | ACHE (0.40) | ACHECYP3A4IDO1TDO2CES2 | |
| SCHEMBL2865478 | 0.81 | GABRA1 (0.43) | CYP3A4ALDH1A1CYP2C9GABRA1GABRB2 | |
| SCHEMBL11258009 | 0.79 | IDO1 (0.42) | ACHECYP3A4IDO1TDO2CES2 | |
| SCHEMBL84442 | 0.79 | GABRA1 (0.50) | ACHECYP3A4IDO1TDO2CES2 | |
| SCHEMBL3406218 | 0.79 | IDO1 (0.42) | ACHECYP3A4IDO1TDO2CES2 | |
| SCHEMBL31852251 | 0.79 | GABRA1 (0.50) | ACHECYP3A4IDO1TDO2CES2 | |
| SCHEMBL15903486 | 0.79 | ACHE (0.43) | ACHECYP3A4IDO1TDO2CES2 | |
| SCHEMBL4219819 | 0.77 | IDO1 (0.41) | ACHECYP3A4IDO1TDO2CES2 | |
| SCHEMBL15247585 | 0.76 | MAPKAPK2 (0.44) | ACHECYP3A4IDO1TDO2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322081-B | Synthesis method of alkyl alkenyl ketone | 南京工业大学 | 2023-05-16 | — | — | CN | disclosed |
| CN-115322081-A | Synthesis method of alkyl alkenyl ketone | 南京工业大学 | 2022-11-11 | — | — | CN | disclosed |
| EP-2448939-B1 | 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ONE DERIVATIVES, THE PREPARATION AND PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2017-03-01 | — | — | EP | disclosed |
| CN-102482286-B | Novel 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives, their preparation and their medical use | SANOFI SA | 2015-07-15 | — | — | CN | disclosed |
| CN-102482285-B | Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI SA | 2015-07-15 | — | — | CN | disclosed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846670-B2 | 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8828997-B2 | 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| EP-2448940-B1 | 6,7,8,9-tetrahydro-pyrimido{1,2-a} pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof | SANOFI SA (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-7816360-B2 | Microsomal triglyceride transfer protein (MTP) inhibitors, used for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and non-insulin dependent diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | MEERPOEL LIEVEN | 2010-01-07 | — | — | US | disclosed |
| US-7504400-B2 | for the treatment of atherosclerosis, pancreatitis, obesity, hyper-triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes; apolipoprotein B secretion inhibitors also for lipid lowering activity; compounds can selectively block MTP at the level of the gut wall in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |
| EP-1751131-B1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-19 | — | — | EP | disclosed |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| CN-1930143-A | MTP inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-14 | — | — | CN | disclosed |
| EP-1751131-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005085226-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-15 | — | — | WO | disclosed |
| EP-0135249-B1 | STYRENE DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1986-11-12 | — | — | EP | disclosed |
| EP-0135249-A1 | Styrene derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | APOB, PNLIP, LPL | ACHE 3353/4885CYP3A4 2551/4885IDO1 3877/4885 |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | PNLIP, LPL, APOB | ACHE 1487/4885CYP3A4 1713/4885IDO1 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.